Member Info for EmeraldCarrots

Up 37%.

Cancer treatment BREAKTHROUGH.

All IMHO.

The sp here will be up over 50% by close of play I think............

All IMHO.

Up 32.1%.

PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCER"

"Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions".

As I said I think we will get bought out.........

This news is quite amazing!!!

All IMHO.

Https://www.medicaldevice-network.com/news/angle-eisai-contract-assay/?cf-view&cf-closed

See yesterdays RNS.

Up 10.4%

RNS about contract with EISAI INC. ?????????

Now up 16.7%

No typo this time, LOL!!!

Sp taking off it seems!!!

Up 14.6%.

Typo. Sorry.

Up 16.6%.

USA money?

Here. Up to you what you do of course but what does the chart and recent news tell you? Have a think.

All IMHO.

Can be monitored over several months...........................

A cancers HER2 status can change over time, which may mean the treatment needs changing....................

Angle's Parsortix system can get the information from a standard blood sample. No surgery just a standard blood sample!

The market need to WAKE UP!!

All IMHO.

Up 12.5% now.

Could be brown trousers time for those short. Wipeout.

All IMHO.

Up 10.4% now.

Yeehaaaa!

Up 8.3%. Barenberg target 120p.

Off we go !!!! My target is a mere 18p!! LOL!!!

All IMHO.

Up 4.2% Target 120p !

Like your post:-

Liquid biopsy company Angle (AGL) has signed a ‘pivotal’ contract that signals a ‘landmark achievement’, says Berenberg.

Analyst Odysseas Manesiotis retained his ‘buy’ recommendation and target price of 120p on the stock, which added over 3% to 12.1p on the first day of trading in 2024. The shares plunged 75% last year.

Manesiotis said the group announced a ‘pivotal contract’ with Eisai Inc of Japan to test oncology drugs that is worth $250,000 over the study’s duration but ‘also marks a significant milestone for Angle, offering potential for extensive follow-up studies and establishing a promising collaboration with a major company in the pharmaceutical industry’.

‘This contract with Eisai Inc represents a landmark achievement for Angle, signifying its entry into high-profile pharmaceutical collaborations and the potential for a transformative impact in oncology therapeutics,’ said Manesiotis.

‘While Angle’s approach remains novel and hence less likely to be trialled during periods of weak biotech funding, we continue to think it offers significant potential in one of the most attractive cancer diagnostics niches, and with a fresh commercial muscle, products and now strong validation, the shares could trade very well as biotech funding recovers.’

All IMHO.

Several % better than it was??

Huge savings on fuel for Cruise ships and Airlines!!!

Good news for World inflation too!!!!!